Advertisement
Online Images in the Medical Sciences| Volume 364, ISSUE 3, e31-e32, September 2022

Concurrent pseudothrombocytopenia and immune thrombocytopenia

  • Author Footnotes
    # Should be considered equal first authors of this report
    Hannah D. Holt
    Footnotes
    # Should be considered equal first authors of this report
    Affiliations
    Department of General Surgery, St. Elizabeth's Medical Center, Brighton MA USA
    Search for articles by this author
  • Author Footnotes
    # Should be considered equal first authors of this report
    Matthew F. Holt
    Footnotes
    # Should be considered equal first authors of this report
    Affiliations
    Department of General Surgery, St. Elizabeth's Medical Center, Brighton MA USA
    Search for articles by this author
  • Robert T. Means Jr.
    Correspondence
    Corresponding author at: Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, P.O. Box 70622, Johnson City TN 37614 USA.
    Affiliations
    Departments of Internal Medicine and Pathology, Quillen College of Medicine, East Tennessee State University, Johnson City TN USA
    Search for articles by this author
  • Author Footnotes
    # Should be considered equal first authors of this report
Published:April 22, 2022DOI:https://doi.org/10.1016/j.amjms.2022.04.023
Concurrent pseudothrombocytopenia and immune thrombocytopenia
Previous ArticlePheochromocytoma-related posterior reversible encephalopathy syndrome
Next ArticleHepatocellular carcinoma with right atrial tumor thrombus
      Psuedothrombocytopenia is a term used to describe platelet clumping due to antiplatelet antibodies dependent on ethylenediaminetetraacetic acid (EDTA), the anticoagulant routinely used for complete blood counts (CBCs). In the presence of pseudothrombocytopenia, hematology analyzers may report a spuriously decreased platelet count.
      • Lippi G
      • Plebani M.
      EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact.
      Clin Chem Lab Med. 2012; 50: 1281-1285
      Review of the peripheral blood smear is recommended as the initial step in the evaluation of thrombocytopenic patients, in part to rule out pseudothrombocytopenia.

      Calverley DC, Garland K, Haley KM, Recht M. Thrombocytopenia caused by immunologic platelet distruction. In: Greer JP, Rodgers GM, Glader B, et al, eds. Wintrobe's Clinical Hematology. Wolters Kluwer; 2019:1072-1095:chap 48.

      Pseudothrombocytopenia is typically confirmed by demonstrating correction of the platelet count with an alternate anticoagulant, usually sodium citrate (Na-citrate).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Lippi G
        • Plebani M.
        EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact.
        Clin Chem Lab Med. 2012; 50: 1281-1285
        View in Article

      2. Calverley DC, Garland K, Haley KM, Recht M. Thrombocytopenia caused by immunologic platelet distruction. In: Greer JP, Rodgers GM, Glader B, et al, eds. Wintrobe's Clinical Hematology. Wolters Kluwer; 2019:1072-1095:chap 48.

        View in Article
        • Salama A.
        Autoimmune thrombocytopenia complicated by EDTA- and/or citrate-dependent pseudothrombocytopenia.
        Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2015; 42: 345-348
        View in Article

      Article info

      Publication history

      Published online: April 22, 2022
      Accepted: April 13, 2022
      Received: August 12, 2021

      Identification

      DOI: https://doi.org/10.1016/j.amjms.2022.04.023

      Copyright

      © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX